RNXT RNXT
Company Profile ↓Company Overview
RNXT (RNXT) is a publicly traded company listed on with a market capitalization of $38.81M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $1.12M (+2511.6% YoY); net profit $-11.17M.
- Trailing 12 Months Year-on-year growth — revenue +2511.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 2,511.63% |
Stock Price Performance
| 1 Year: | -12.40% |
| 6 Months: | +4.95% |
| 3 Months: | +14.22% |
| 1 Month: | +14.22% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)65.62 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 197.00K | 422.00K | 266.00K | 238.00K | 563.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 94.00K | 152.00K | 53.00K | 28.00K | 84.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 103.00K | 270.00K | 213.00K | 210.00K | 479.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.21M | 2.95M | 3.41M | 3.73M | 3.95M |
| Operating Income | - | - | -910.00K | -1.05M | -866.00K | -1.40M | -3.00M | -2.61M | -2.16M | -3.26M | -3.38M | -2.98M | -2.48M | -3.03M | -2.83M | -3.11M | -2.68M | -3.20M | -3.52M | -3.47M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.11M | -2.68M | -3.20M | -3.52M | -3.47M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.42M | -2.90M | -2.91M | -2.94M | -3.52M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.05M | -773.00K | -1.10M | -1.15M | -1.31M | -1.51M | -3.00M | -2.59M | -2.14M | -3.26M | -2.33M | -1.42M | -1.08M | -2.39M | -2.47M | -2.42M | -2.90M | -2.91M | -2.94M | -3.52M |
| Diluted EPS | - | - | - | - | - | - | - | -0.29 | -0.24 | -0.36 | -0.22 | -0.13 | -0.07 | -0.10 | -0.10 | -0.08 | -0.08 | -0.08 | - | -0.09 |
| R&D Expense | - | - | 727.00K | 635.00K | 536.00K | 767.00K | 1.29M | 1.39M | 846.00K | 1.34M | 1.93M | 1.63M | 1.26M | 1.54M | 1.65M | 1.64M | 1.43M | 1.69M | - | 1.23M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 43.00K | 1.12M |
| Cost of Revenue | - | - | - | 0 | 0 | 327.00K |
| Gross Profit | - | - | - | 0 | 43.00K | 796.00K |
| Operating Expenses | - | - | 9.95M | 11.40M | 11.01M | 13.31M |
| Operating Income | -3.20M | - | -9.95M | -11.40M | -10.97M | -12.51M |
| EBITDA | - | - | -9.94M | -11.40M | -10.97M | -12.51M |
| Interest Expense | - | 834.00K | - | - | - | - |
| Pretax Income | - | - | -9.89M | -10.23M | -8.81M | -11.17M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -3.80M | - | -9.89M | -10.23M | -8.81M | -11.17M |
| Diluted EPS | - | - | -1.09 | -0.99 | -0.40 | -0.32 |
| R&D Expense | 2.39M | 3.04M | 4.30M | 5.67M | 6.03M | 6.27M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.91M | - | 7.26M | 1.47M | 8.12M | 8.10M |
| Current Assets | - | - | - | 7.26M | 1.47M | 7.83M | 7.89M |
| Cash & Equivalents | - | 1.79M | - | 4.39M | 1.17M | 7.15M | 7.02M |
| Inventory | - | - | - | - | - | 0 | 189.00K |
| Receivables | - | - | - | - | 0 | 43.00K | 139.00K |
| Total Liabilities | - | 4.12M | - | 1.10M | 4.47M | 3.64M | 2.67M |
| Current Liabilities | - | 4.10M | - | 1.10M | 1.18M | 1.91M | 1.96M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 0 | 278.00K | 212.00K |
| Total Equity | -10.93M | -14.66M | - | 6.16M | -3.00M | 4.48M | 5.42M |
| Shares Outstanding | - | - | - | 9.10M | 10.69M | 24.03M | 36.61M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.53M | - | -8.81M | -10.26M | -9.12M | -10.97M |
| Investing Cash Flow | - | - | -2.03M | 2.03M | -12.00K | -2.00K |
| Financing Cash Flow | 3.20M | - | 42.00K | 5.01M | 15.12M | 10.85M |
| Capital Expenditure | - | -15.00K | - | - | -12.00K | -2.00K |
| Free Cash Flow | - | - | -8.81M | -10.26M | -9.14M | -10.97M |
| Net Change in Cash | - | - | -10.80M | -3.22M | 5.98M | -130.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 100.0% | 70.9% |
| Operating Margin % | - | - | - | - | -25,511.6% | -1,114.1% |
| Net Margin % | - | - | - | - | -20,497.7% | -994.5% |
| ROE % | 25.9% | - | -160.5% | 341.1% | -196.8% | -206.0% |
| ROCE % | 146.8% | - | -161.4% | -3,916.2% | -176.7% | -204.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RNXT
RenovoRx Webinar to Explore Local Chemotherapy for Pancreatic Cancer - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQRDhiVmZOQXVZa0FZVVBZeFhtN1NKZ1cyN2tabHlwVmh4MXNqMnJxOVBFUXBuWVVxaVcyQ1pFUFBGQVlQMWpZQlpJVktoMWpqcGJLTk1NM0dPMVVEenlPRkVuNE9ZVGNKaWtzcWRTd2otLUNuVE9sNlRubW1uSGE3Mlpkc1RUUWFTTUt3Tk…
RenovoRx, Inc. Revenue Breakdown – NASDAQ:RNXT - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFA0S2I3ZWhxeVc1WDdINUkwYkNqTENXVm5VUmFaNlhMajNnYkJQWlFmUEtBUHBXYlpaSGFrOHVPaVo3X0wwM0VodmpzQTg3Ukx0dkVpQTRKNWtNd0M0VGhYLVUtTm5XWlJHTVc0aGZFdE40QTZJQWh3?oc=5" target="_blank">RenovoR…
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQV09sb3hnX2loQURkU2VpLVJubGMyR1Q5ZWZmcy1pdW1rTmxDajRuRE5FSGZEbXF1T0lPWDg1V0czVEV3TjlvNUgwZVVQT0xmbVpWTUx2WE1Qc0pRQlRjNmNNTkJOV2dKWktQODJBSnczN3d3SWFBNTg5bmp4alFFWXFMOUhkZEhheHFMSF…
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), RenovoRx (RNXT) and ACADIA Pharmaceuticals (ACAD) - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMipAJBVV95cUxOVmtfMmNKWng1UXJTV195M3V5cmZGRU5BalBHTnBXaW5uSm1TbFFhMk1lZWxSUW5tbXdadGpkVGZ1R2lWaEVsYktMMXV6MEZlZmNoTkptdWI2UDNiVUNTY25GanhSR2V1N3BseVpvZHZDaklKSnJleDVXUkowMG1ka0I5b01RMzVaWUlOR3…
RenovoRx, Inc. (NASDAQ:RNXT): Are Analysts Optimistic? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNRGVpSXpPeXU1em5oZHNieHVFaUNoZHY0cUJjcVlDdHk4eXdxLWVSQ2VxMkFPbVdWRzhOX2JEX0hySk1ic1RHclg3VTIwQWRkUklRVm9LV3MzMERkWGRfQXFON3B1bkFLU2xVMDZfQmVqa005X3FTcHVvT1dVUHp4bl9ZR2tVamI4YUNSUE…
RNXT|RenovoRx Inc|Price:1.040|Chg%:+0.082 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1sOU1fS3NFdlR3Qm83cDV1NUZOZkVTcVZIdlhtUGtHX1BqOWtuLXd3Zk5BMXBIVkVxZGMtNFFQeUxMUGxRZE5SRW5kekZIRjlKWEFiSmp5cGFQZEgxS1hTcTNmd1BJTkRrRVVpTHNR?oc=5" target="_blank">RNXT|RenovoRx Inc|P…
RNXT — Frequently Asked Questions
What is the current share price of RNXT?
As of 2026-08-05 17:25 PDT, RNXT trades at $1.06 on NASDAQ/NYSE. Its 52-week range is $0.73 to $1.34.
What is the market capitalisation of RNXT?
RNXT has a market capitalisation of $38.81M on NASDAQ/NYSE.
What is the P/E ratio of RNXT?
RNXT trades at a trailing price-to-earnings (P/E) ratio of -3.31. Its price-to-book (P/B) ratio is 7.16.
Is RNXT a good stock to buy?
This page provides a data-driven analysis of RNXT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.